The study includes 17 patients who were treated with bone marrow concentrate for non-union fractures. Researchers used Cesca Therapeutics’ proprietary technology to process bone marrow aspirate at the point of care.
Journal of Stem Cells Research, Development and Therapy published the results.
Here are four observations:
1. The bone marrow concentrate is designed to stimulate bone regeneration and healing of the fracture.
2. Fourteen of the patients experienced bone regeneration and fracture healing.
3. The bone marrow concentrate is administered in a single sitting, decreasing infection risk.
4. Researchers noted no adverse reactions during or following the procedure.
“Cell therapy using bone marrow concentrate represents a promising new method for treating atrophic non-union fractures in patients with a history of failed primary surgical intervention,” said Dr. Venkatesh Ponemone, study director. “We are encouraged by these results and look forward to making this method routinely available.”
More articles on devices:
Orthofix net sales total $104.1M; Spine fixation segment down 5.9% in Q2 — 15 key notes
Mazor Q2 revenue hits $8.3M after Medtronic investment: 10 key notes
Smith & Nephew revenue hits $1.1B, up 2% in Q2: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
